TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14735021

Group type: EXPERIMENTAL
Intervention: Subarachnoid anaesthesia with 12.75 mg 0.5% hyperbaric bupivacaine
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Subarachnoid anaesthesia with 12.75 mg 0.5% hyperbaric bupivacaine and 15 mg fentanyl
Number of subjects: 68

Group type: COMPARATOR
Intervention: Natural delivery
Number of subjects: 68

Group type: COMPARATOR
Intervention: Caesarean delivery with general anaesthesia
Number of subjects: 68
Study: 11054156

Group type: EXPERIMENTAL
Intervention: Pramipexole
Number of subjects: 7
Study: 8615356

Group type: COMPARATOR
Intervention: Synthetic beta-carotene (40 mg daily for 14 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Natural beta-carotene from Dunaliella bardawil (40 mg daily for 14 days)
Number of subjects: 0
Study: 1417224

Group type: EXPERIMENTAL
Intervention: Stentless pericardial valves
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Stentless valves
Number of subjects: 57
Study: 6706069

Group type: EXPERIMENTAL
Intervention: 3-day clear liquid diet with laxatives and enemas
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: 3-day minimum-residue diet with laxatives and enemas
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: 1-day minimum-residue diet with laxatives and enemas
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Golytely
Number of subjects: 197

Group type: COMPARATOR
Intervention: Breath hydrogen and methane levels in group 3
Number of subjects: 197

Group type: COMPARATOR
Intervention: Breath hydrogen and methane levels in group 4
Number of subjects: 197

Group type: COMPARATOR
Intervention: Hematologic and biochemical parameters
Number of subjects: 197
Study: 31241491

Group type: EXPERIMENTAL
Intervention: Topical nifedipine 3% ointment
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 30328547

Group type: EXPERIMENTAL
Intervention: PFA‐7 at 2% of dry matter intake (DMI)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: PFA‐7 at 4% of dry matter intake (DMI)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control (without PFA‐7)
Number of subjects: 21
Study: 29297588

Group type: EXPERIMENTAL
Intervention: Various treatments for lichen planopilaris
Number of subjects: 32
Study: 27642172

Group type: EXPERIMENTAL
Intervention: Extended magnetic resonance imaging (eMRI) scale
Number of subjects: 0
Study: 25318000

Group type: EXPERIMENTAL
Intervention: Propofol & sufentanil (PS) group received 0.1 μg/kg sufentanil and 1-2 mg/kg propofol
Number of subjects: 439

Group type: COMPARATOR
Intervention: Propofol & fentanyl (PF) group received 1 μg/kg fentanyl and 1-2 mg/kg propofol
Number of subjects: 439

Group type: COMPARATOR
Intervention: Propofol & remifentanil (PR) group received 1 μg/kg remifentanil and 1-2 mg/kg propofol
Number of subjects: 439

Group type: COMPARATOR
Intervention: Propofol & half-fentanil (Pf) group received 0.5 μg/kg fentanyl and 1-2 mg/kg propofol
Number of subjects: 439

Group type: COMPARATOR
Intervention: Propofol & half-sufentanil (Ps) group received 0.05 μg/kg sufentanil and 1-2 mg/kg propofol
Number of subjects: 439

Group type: COMPARATOR
Intervention: Propofol & half-remifentanil (Pr) group received 0.5 μg/kg remifentanil and 1-2 mg/kg propofol
Number of subjects: 439
Study: 22318246

Group type: EXPERIMENTAL
Intervention: Everolimus (EVL) plus reduced-exposure cyclosporine A (CsA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard dose CsA
Number of subjects: 30
Study: 20488408

Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS)
Number of subjects: 334

Group type: COMPARATOR
Intervention: Surgical endarterectomy (CEA)
Number of subjects: 334
Study: 18588360

Group type: EXPERIMENTAL
Intervention: Rapid-cycling bipolar I disorder
Number of subjects: 245

Group type: COMPARATOR
Intervention: Rapid-cycling bipolar II disorder
Number of subjects: 245
Study: 15830389

Group type: COMPARATOR
Intervention: Skin-prick testing (SPT) in children aged 2-<5 years
Number of subjects: 149

Group type: COMPARATOR
Intervention: Skin-prick testing (SPT) in children aged 5-10 years
Number of subjects: 149
Study: 11819152

Group type: EXPERIMENTAL
Intervention: Anticholinergic drug withdrawal
Number of subjects: 21
Study: 10909492

Group type: EXPERIMENTAL
Intervention: Color Doppler ultrasound examination
Number of subjects: 306

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 306
Study: 7481852

Group type: EXPERIMENTAL
Intervention: Paclitaxel (Taxol)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination regimens
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single-agent regimens
Number of subjects: 0
Study: 2023020

Group type: EXPERIMENTAL
Intervention: Simple notification of primary care provider (n = 102)
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Intensive notification (n = 104)
Number of subjects: 292

Group type: COMPARATOR
Intervention: Control group (n = 88)
Number of subjects: 292
Study: 7342654

Group type: EXPERIMENTAL
Intervention: AR programme
Number of subjects: 30

Group type: COMPARATOR
Intervention: RAMP programme
Number of subjects: 30
Study: 31474719

Group type: EXPERIMENTAL
Intervention: Intravenous administration of midazolam at doses of 5, 15, and 30 µg/kg
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Oral administration of midazolam at doses of 15, 50, and 100 µg/kg
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Urinary excretion of midazolam after oral administration
Number of subjects: 19
Study: 28736211

Group type: EXPERIMENTAL
Intervention: Modern neuroscience approach (pain neuroscience education and cognition-targeted exercise therapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care evidence-based physiotherapy
Number of subjects: 0
Study: 26078287

Group type: EXPERIMENTAL
Intervention: High-dose vitamin D supplementation
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (baseline measurements)
Number of subjects: 24
Study: 22819332

Group type: EXPERIMENTAL
Intervention: Flapless (FL) technique
Number of subjects: 40

Group type: COMPARATOR
Intervention: Flap (F) technique
Number of subjects: 40
Study: 21127424

Group type: EXPERIMENTAL
Intervention: IV ibuprofen 800 mg every 6 hours for 120 hours (5 days)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 19455620

Group type: EXPERIMENTAL
Intervention: Ambrisentan (10 mg) with Tadalafil (40 mg QD)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Tadalafil (40 mg) with Ambrisentan (10 mg QD)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Combination of Ambrisentan and Tadalafil
Number of subjects: 26
Study: 16791807

Group type: EXPERIMENTAL
Intervention: BMC therapy
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 27
Study: 15646031

Group type: EXPERIMENTAL
Intervention: Garlic pearls (GP) 250 mg per day for 2 months
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (normotensive individuals)
Number of subjects: 20
Study: 11198728

Group type: EXPERIMENTAL
Intervention: Nisoldipine (10-40 mg)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Amlodipine (2.5-10 mg)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Nisoldipine
Number of subjects: 161
Study: 9299672

Group type: EXPERIMENTAL
Intervention: Senna (n = 44)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Loperamide (n = 43)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Baseline measurements
Number of subjects: 66

Group type: COMPARATOR
Intervention: Change in WGTT
Number of subjects: 66
Study: 8285333

Group type: EXPERIMENTAL
Intervention: Epidural diamorphine 2.5 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous patient-controlled analgesia using diamorphine
Number of subjects: 0
Study: 3505874

Group type: EXPERIMENTAL
Intervention: Experimental group (life circumstances at age 40 reviewed)
Number of subjects: 362

Group type: COMPARATOR
Intervention: Control group (completed personality inventory twice under standard directions)
Number of subjects: 362
Study: 29117913

Group type: EXPERIMENTAL
Intervention: Personalized Intervention for Depressed Patients with Chronic Obstructive Pulmonary Disease (PID‐C)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Problem‐Solving Adherence (PSA) intervention
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group (PID‐C vs PSA)
Number of subjects: 101
Study: 28139161

Group type: EXPERIMENTAL
Intervention: Liposome-encapsulated Aloe vera gel extract (AGE) for 5 weeks
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control group (AGE) for 5 weeks
Number of subjects: 180
Study: 25585050

Group type: EXPERIMENTAL
Intervention: Mindfulness-oriented meditation (8-week duration)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group with alcohol dependence
Number of subjects: 0
Study: 23545908

Group type: EXPERIMENTAL
Intervention: Skin-lightening cream (SLC) with 4% hydroquinone (HQ)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Triple combination cream (TCC) with 4% hydroquinone (HQ), 0.05% tretinoin, and 0.01% fluocinolone acetonide
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Skin-lightening cream (SLC)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Triple combination cream (TCC)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both creams
Number of subjects: 20
Study: 20739557

Group type: EXPERIMENTAL
Intervention: Context group (negative expectation)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (no information)
Number of subjects: 38
Study: 17976226

Group type: EXPERIMENTAL
Intervention: BIS monitoring (available data)
Number of subjects: 160

Group type: COMPARATOR
Intervention: BIS monitoring (concealed)
Number of subjects: 160
Study: 16991077

Group type: EXPERIMENTAL
Intervention: 1 dose of trivalent inactivated influenza vaccine (TIV)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: 2 doses of trivalent inactivated influenza vaccine (TIV)
Number of subjects: 232
Study: 15050006

Group type: EXPERIMENTAL
Intervention: Patients with TCC
Number of subjects: 91

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 91
Study: 11444449

Group type: EXPERIMENTAL
Intervention: IT morphine 300 microg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline 0.5 mL
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: IT neostigmine 50 microg
Number of subjects: 60
Study: 9505738

Group type: EXPERIMENTAL
Intervention: Sevoflurane group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 7996111

Group type: EXPERIMENTAL
Intervention: Salicylic acid (2 x 250 mg)
Number of subjects: 588

Group type: EXPERIMENTAL
Intervention: Acetaminophen (2 x 250 mg)
Number of subjects: 588

Group type: EXPERIMENTAL
Intervention: Ibuprofen (2 x 250 mg)
Number of subjects: 588

Group type: EXPERIMENTAL
Intervention: Ketoprofen (2 x 250 mg)
Number of subjects: 588

Group type: EXPERIMENTAL
Intervention: Acetaminophen (2 x 250 mg) plus codeine (2 x 250 mg)
Number of subjects: 588

Group type: EXPERIMENTAL
Intervention: Penicillin (2 x 250 mg)
Number of subjects: 588

Group type: EXPERIMENTAL
Intervention: Erythromycin base (2 x 250 mg)
Number of subjects: 588

Group type: EXPERIMENTAL
Intervention: Penicillin plus ibuprofen (2 x 250 mg)
Number of subjects: 588

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (2 x 250 mg) plus penicillin (2 x 250 mg)
Number of subjects: 588

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 588
Study: 3344883

Group type: EXPERIMENTAL
Intervention: Concentric isokinetic internal and external shoulder rotation
Number of subjects: 22

Group type: COMPARATOR
Intervention: Eccentric isokinetic internal and external shoulder rotation
Number of subjects: 22
Study: 31957958

Group type: EXPERIMENTAL
Intervention: Anhydrous gel with TriHex peptides
Number of subjects: 5

Group type: COMPARATOR
Intervention: Standard skin regimen
Number of subjects: 5
Study: 29746713

Group type: EXPERIMENTAL
Intervention: SCY-078 (1250 mg loading dose on day 1 followed by 750 mg once daily for 7 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rosiglitazone (4 mg single oral dose)
Number of subjects: 0
Study: 28081962

Group type: EXPERIMENTAL
Intervention: Cetuximab plus FOLFIRI (5‐fluorouracil, leucovorin, irinotecan)
Number of subjects: 367

Group type: COMPARATOR
Intervention: FOLFIRI (5‐fluorouracil, leucovorin, irinotecan)
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: Cetuximab plus FOLFIRI
Number of subjects: 367

Group type: COMPARATOR
Intervention: FOLFIRI
Number of subjects: 367
Study: 26242213

Group type: EXPERIMENTAL
Intervention: TF-TAVR (Transfemoral TAVR)
Number of subjects: 531

Group type: EXPERIMENTAL
Intervention: TA-TAVR (Transapical TAVR)
Number of subjects: 531
Study: 24568171

Group type: EXPERIMENTAL
Intervention: 9.5 percent hydrogen-peroxide whitening strips (Strip group)
Number of subjects: 45

Group type: COMPARATOR
Intervention: In-office light plus 25 percent hydrogen-peroxide whitening gel treatment (In-office group)
Number of subjects: 45
Study: 21161543

Group type: EXPERIMENTAL
Intervention: Inert sock liner
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Complete occlusion with a water vapor impermeable wet dressing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional skin care methods
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal skin
Number of subjects: 0
Study: 18272931

Group type: EXPERIMENTAL
Intervention: 1 g/d GPLC
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 3 g/d GPLC
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 16494566

Group type: EXPERIMENTAL
Intervention: Transcendental Meditation (TM) practitioners
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control subjects (non-meditators)
Number of subjects: 20
Study: 12597468

Group type: EXPERIMENTAL
Intervention: Home nursing care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Respite services
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Social networks and activity enhancement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Problem solving and education
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group work
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Targeted services delivered solely to carers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomized control trial (RCT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single group methodology
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Facilitator feedback
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall evidence
Number of subjects: 0
Study: 11092410

Group type: EXPERIMENTAL
Intervention: 800 IU cholecalciferol/day for 2 years
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study: 9352147

Group type: EXPERIMENTAL
Intervention: Indirect antiglobulin test with xylene eluates
Number of subjects: 35
Study: 8185728

Group type: EXPERIMENTAL
Intervention: Antitachycardia pacing (burst or autodecremental ramp)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Antitachycardia pacing
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Detection algorithms (sudden onset, sustained rate duration, cycle length stability)
Number of subjects: 42
Study: 3519005

Group type: EXPERIMENTAL
Intervention: DDAVP (0.4 microgram/kg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: DDAVP (0.4 microgram/kg) in subjects with cranial diabetes insipidus
Number of subjects: 6
Study: 28952192

Group type: EXPERIMENTAL
Intervention: Rubber bristles interdental cleaner (RBIC)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Interdental brush (IDB)
Number of subjects: 42
Study: 27102847

Group type: EXPERIMENTAL
Intervention: Coconut oil (COC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control bread (CTR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Butter (BTR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Grapeseed oil (GRP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Olive oil (OLV)
Number of subjects: 0
Study: 23572444

Group type: EXPERIMENTAL
Intervention: Telephone-facilitated depression care
Number of subjects: 124

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 124
Study: 22237259

Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 242

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 242
Study: 20530648

Group type: EXPERIMENTAL
Intervention: Scapula-oriented exercise group (n = 16)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: General exercise group (n = 16)
Number of subjects: 32
Study: 18772447

Group type: EXPERIMENTAL
Intervention: Low-dose rt-PA (0.3 mg/kg or 0.45 mg/kg) plus eptifibatide (75 microg/kg bolus followed by 0.75 microg/kg per min infusion for 2 hours)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Standard-dose rt-PA (0.9 mg/kg)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Combination treatment group (low-dose rt-PA plus eptifibatide)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Standard-dose rt-PA group
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Combination treatment group
Number of subjects: 94
Study: 15889948

Group type: EXPERIMENTAL
Intervention: Olanzapine (5-20 mg/day, N = 370)
Number of subjects: 833

Group type: EXPERIMENTAL
Intervention: Olanzapine/fluoxetine combination (6/25, 6/50, or 12/50 mg/day; N = 86)
Number of subjects: 833

Group type: COMPARATOR
Intervention: Placebo (N = 377)
Number of subjects: 833
Study: 12534412

Group type: EXPERIMENTAL
Intervention: Nitazoxanide (100 mg b.d. for age 2-3 years; 200 mg b.d. for age 4-11 years; 500 mg b.d. for age > 12 years)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Number of subjects: 100
Study: 10818026

Group type: EXPERIMENTAL
Intervention: Intensive glucose control policy with a sulphonylurea or insulin
Number of subjects: 3867

Group type: COMPARATOR
Intervention: Conventional (primarily diet) glucose control policy
Number of subjects: 3867
Study: 8679354

Group type: EXPERIMENTAL
Intervention: EMLA cream (lignocaine-prilocaine) applied for 8 hours after burn injury
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo treatment applied to contralateral leg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: EMLA cream (lignocaine-prilocaine)
Number of subjects: 12
Study: 1877711

Group type: EXPERIMENTAL
Intervention: Ivermectin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Diethylcarbamazine (DEC)
Number of subjects: 60
Study: 7049583

Group type: EXPERIMENTAL
Intervention: Chlormezanone 200 mg
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Chlormezanone 400 mg
Number of subjects: 76
Study: 30626406

Group type: EXPERIMENTAL
Intervention: Muscle Relaxant (MR group)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Saline (Control group)
Number of subjects: 128
Study: 30445896

Group type: EXPERIMENTAL
Intervention: Cabotegravir LA 800 mg every 12 weeks after 4 weeks of oral cabotegravir 30 mg
Number of subjects: 115

Group type: COMPARATOR
Intervention: Placebo (saline) every 12 weeks after 4 weeks of placebo tablets
Number of subjects: 115
Study: 27002645

Group type: EXPERIMENTAL
Intervention: 200 mg of caffeine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24461333

Group type: EXPERIMENTAL
Intervention: Intralase 60 kHz laser
Number of subjects: 60

Group type: COMPARATOR
Intervention: Visumax 500 kHz laser
Number of subjects: 60
Study: 22349648

Group type: EXPERIMENTAL
Intervention: Scopolamine (4μg/kg)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 19641353

Group type: EXPERIMENTAL
Intervention: Rectus fascial sling procedure incorporated into RRP (group 1)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Standard RRP without suspension operation (group 2)
Number of subjects: 86
Study: 17656420

Group type: EXPERIMENTAL
Intervention: Daily vitamin D 800 iu plus calcium 1,200 mg
Number of subjects: 205

Group type: COMPARATOR
Intervention: Daily calcium 1,200 mg (Control)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 205
Study: 16306204

Group type: EXPERIMENTAL
Intervention: AA1.5 (1.5 g/kg/d for 20 h followed by 3.0 g/kg/d for 5 h)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: AA3.0 (3.0 g/kg/d for 20 h followed by 1.5 g/kg/d for 5 h)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: AA-Ext (1.5 g/kg/d for 20 h followed by 3.0 g/kg/d for 20 h)
Number of subjects: 3
Study: 12421176

Group type: EXPERIMENTAL
Intervention: Tension-free vaginal tape (TVT) procedure
Number of subjects: 79

Group type: COMPARATOR
Intervention: Laparoscopic colposuspension
Number of subjects: 79
Study: 10832809

Group type: EXPERIMENTAL
Intervention: Verapamil (5 mg i.v. + 2 microg/kg/min over 24 hours)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 9366659

Group type: EXPERIMENTAL
Intervention: Family therapy
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Individual supportive therapy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Natural outcome of anorexia nervosa
Number of subjects: 80
Study: 1567031

Group type: COMPARATOR
Intervention: Saline (group 0)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 0.25 micrograms/kg fentanyl (group 25)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 0.5 micrograms/kg fentanyl (group 50)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 0.75 micrograms/kg fentanyl (group 75)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 0.5 micrograms/kg and 0.75 micrograms/kg fentanyl
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 120
Study: 3901756

Group type: EXPERIMENTAL
Intervention: Indomethacin 50 mg three times daily
Number of subjects: 10

Group type: COMPARATOR
Intervention: Naproxen 250 or 500 mg three times daily
Number of subjects: 10
Study: 30504928

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 0.5 mg/kg, iv
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 29246679

Group type: EXPERIMENTAL
Intervention: Finned, cementless central pegged glenoid component (CL component)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional cemented pegged glenoid component (P component)
Number of subjects: 50
Study: 26836763

Group type: EXPERIMENTAL
Intervention: Tetravalent dengue vaccine (CYD-TDV)
Number of subjects: 3615

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3615
Study: 24112594

Group type: EXPERIMENTAL
Intervention: Chewing gum for at least 20 minutes every 2 hours starting at the time of capsule ingestion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no chewing gum)
Number of subjects: 0